Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 451 to 460 of 599 total matches.

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
cancer, The Medical Letter ® Vol. 64 (1647) April 4, 2022 52 but the absolute risk was low.11 ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
reactions, and non-melanoma skin cancer.12 Long-term thiopurine use has been associated with an increased ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Octreotide - A Synthetic Somatostatin

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS Acromegaly AIDS Cancer chemotherapy ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Med Lett Drugs Ther. 1989 Jul 14;31(796):66-8 |  Show IntroductionHide Introduction

Mifepristone (RU 486)

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990  (Issue 833)
of Cushing’s disease and breast cancer, but no manufacturer has applied to the US Food and Drug Administration ...
Recent articles in the press have suggested that mifepristone (RU 486 - Roussel Uclaf) can effectively and safely induce an abortion. The drug is currently available only in France and China, but the manufacturer has also applied for a license in the United Kingdom. Mifepristone has been used on an investigational basis in the USA as an abortifacient and for treatment of Cushing's disease and breast cancer, but no manufacturer has applied to the US Food and Drug Administration for approval to market the drug in this country.
Med Lett Drugs Ther. 1990 Dec 14;32(833):112-4 |  Show IntroductionHide Introduction

Intracavernous Injection of Alprostadil for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 1995  (Issue 958)
surgery for bladder or prostate cancer, or castration (Medical Letter, 32:116, 1990). These drugs ...
An aqueous formulation of alprostadil (prostaglandin E 1 ; - Upjohn) has been approved by the US Food and Drug Administration (FDA) for injection into the corpus cavernosum to treat erectile dysfunction. The drug is also marketed as Prostin VR, an alcohol-containing formulation, for intravenous use in newborns with congenital heart disease to maintain the patency of the ductus arteriosus.
Med Lett Drugs Ther. 1995 Sep 29;37(958):83-4 |  Show IntroductionHide Introduction

Umbilical Cord Blood for Bone Marrow Transplantation

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996  (Issue 981)
cord blood for Cancer chemotherapy and umbilical cord blood transplantation Fulvicin Transplantation ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Med Lett Drugs Ther. 1996 Aug 16;38(981):71-2 |  Show IntroductionHide Introduction

Two New Retinoids for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997  (Issue 1013)
radiation (PUVA) is effective, but increases the risk of skin cancer. Systemic drugs, usually reserved ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):105-6 |  Show IntroductionHide Introduction

Gemtuzumab for Relapsed Acute Myeloid Leukemia

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000  (Issue 1083)
Idamycin Cancer chemotherapy gemtuzumab ...
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy
Med Lett Drugs Ther. 2000 Jul 24;42(1083):67-8 |  Show IntroductionHide Introduction

Ezetimibe Revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
types of cancer in patients taking the simvastatin-ezetimibe combination; other studies have not found ...
In recent months, both the lay media and some medical experts have raised concerns about the effectiveness and safety of ezetimibe, a widely used drug that prevents absorption of cholesterol from the GI tract. Ezetimibe is available alone as Zetia and in combination with 10, 20, 40 and 80 mg of simvastatin (Zocor, and others) as Vytorin.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):67-8 |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
with other drugs that prolong the QT interval or cause serotonin syndrome BCRP = breast cancer resistance protein ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721f |  Show IntroductionHide Introduction